The etiopathogenesis of Parkinson disease and suggestions for future research. Part II

Irene Litvan; Marie Francoise Chesselet; Thomas Gasser; Donato A. Di Monte; Davis Parker; Theo Hagg; John Hardy; Peter Jenner; Richard H. Myers; Donald Price; Mark Hallett; William J. Langston; Anthony E. Lang; Glenda Halliday; Walter Rocca; Charles Duyckaerts; Dennis W. Dickson; Yoav Ben-Shlomo; Christopher G. Goetz; Eldad Melamed

doi:10.1097/nen.0b013e318053716a

The etiopathogenesis of Parkinson disease and suggestions for future research. Part II

Irene Litvan, Marie Francoise Chesselet, Thomas Gasser, Donato A. Di Monte, Davis Parker, Theo Hagg, John Hardy, Peter Jenner, Richard H. Myers, Donald Price, Mark Hallett, William J. Langston, Anthony E. Lang, Glenda Halliday, Walter Rocca, Charles Duyckaerts, Dennis W. Dickson, Yoav Ben-Shlomo, Christopher G. Goetz, Eldad Melamed

Research output: Contribution to journal › Review article › peer-review

35 Scopus citations

Abstract

We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors. Although there is extensive new information on the etiology and pathogenesis of PD, which may advance its treatment, new syntheses of this information are needed. The second part of this two-part, state-of-the-art review by leaders in PD research critically examines the research field to identify areas for which new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part II are genetics, animal models, and oxidative stress.

Original language	English (US)
Pages (from-to)	329-336
Number of pages	8
Journal	Journal of Neuropathology and Experimental Neurology
Volume	66
Issue number	5
DOIs	https://doi.org/10.1097/nen.0b013e318053716a
State	Published - May 2007

Keywords

Lewy bodies
Parkinson disease
Synucleinopathies

ASJC Scopus subject areas

Pathology and Forensic Medicine
Neurology
Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1097/nen.0b013e318053716a

Cite this

Litvan, I., Chesselet, M. F., Gasser, T., Di Monte, D. A., Parker, D., Hagg, T., Hardy, J., Jenner, P., Myers, R. H., Price, D., Hallett, M., Langston, W. J., Lang, A. E., Halliday, G., Rocca, W., Duyckaerts, C., Dickson, D. W., Ben-Shlomo, Y., Goetz, C. G., & Melamed, E. (2007). The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. Journal of Neuropathology and Experimental Neurology, 66(5), 329-336. https://doi.org/10.1097/nen.0b013e318053716a

Litvan, I, Chesselet, MF, Gasser, T, Di Monte, DA, Parker, D, Hagg, T, Hardy, J, Jenner, P, Myers, RH, Price, D, Hallett, M, Langston, WJ, Lang, AE, Halliday, G, Rocca, W, Duyckaerts, C, Dickson, DW, Ben-Shlomo, Y, Goetz, CG & Melamed, E 2007, 'The etiopathogenesis of Parkinson disease and suggestions for future research. Part II', Journal of Neuropathology and Experimental Neurology, vol. 66, no. 5, pp. 329-336. https://doi.org/10.1097/nen.0b013e318053716a

@article{52dfb44c3a5d4373b6b916f2d8aac95c,

title = "The etiopathogenesis of Parkinson disease and suggestions for future research. Part II",

abstract = "We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors. Although there is extensive new information on the etiology and pathogenesis of PD, which may advance its treatment, new syntheses of this information are needed. The second part of this two-part, state-of-the-art review by leaders in PD research critically examines the research field to identify areas for which new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part II are genetics, animal models, and oxidative stress.",

keywords = "Lewy bodies, Parkinson disease, Synucleinopathies",

author = "Irene Litvan and Chesselet, {Marie Francoise} and Thomas Gasser and {Di Monte}, {Donato A.} and Davis Parker and Theo Hagg and John Hardy and Peter Jenner and Myers, {Richard H.} and Donald Price and Mark Hallett and Langston, {William J.} and Lang, {Anthony E.} and Glenda Halliday and Walter Rocca and Charles Duyckaerts and Dickson, {Dennis W.} and Yoav Ben-Shlomo and Goetz, {Christopher G.} and Eldad Melamed",

year = "2007",

month = may,

doi = "10.1097/nen.0b013e318053716a",

language = "English (US)",

volume = "66",

pages = "329--336",

journal = "Journal of neuropathology and experimental neurology",

issn = "0022-3069",

number = "5",

}

TY - JOUR

T1 - The etiopathogenesis of Parkinson disease and suggestions for future research. Part II

AU - Litvan, Irene

AU - Chesselet, Marie Francoise

AU - Gasser, Thomas

AU - Di Monte, Donato A.

AU - Parker, Davis

AU - Hagg, Theo

AU - Hardy, John

AU - Jenner, Peter

AU - Myers, Richard H.

AU - Price, Donald

AU - Hallett, Mark

AU - Langston, William J.

AU - Lang, Anthony E.

AU - Halliday, Glenda

AU - Rocca, Walter

AU - Duyckaerts, Charles

AU - Dickson, Dennis W.

AU - Ben-Shlomo, Yoav

AU - Goetz, Christopher G.

AU - Melamed, Eldad

PY - 2007/5

Y1 - 2007/5

N2 - We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors. Although there is extensive new information on the etiology and pathogenesis of PD, which may advance its treatment, new syntheses of this information are needed. The second part of this two-part, state-of-the-art review by leaders in PD research critically examines the research field to identify areas for which new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part II are genetics, animal models, and oxidative stress.

AB - We are at a critical juncture in our knowledge of the etiology and pathogenesis of Parkinson disease (PD). It is clear that PD is not a single entity simply resulting from a dopaminergic deficit; rather it is most likely caused by a combination of genetic and environmental factors. Although there is extensive new information on the etiology and pathogenesis of PD, which may advance its treatment, new syntheses of this information are needed. The second part of this two-part, state-of-the-art review by leaders in PD research critically examines the research field to identify areas for which new knowledge and ideas might be helpful for treatment purposes. Topics reviewed in Part II are genetics, animal models, and oxidative stress.

KW - Lewy bodies

KW - Parkinson disease

KW - Synucleinopathies

UR - http://www.scopus.com/inward/record.url?scp=34247871430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247871430&partnerID=8YFLogxK

U2 - 10.1097/nen.0b013e318053716a

DO - 10.1097/nen.0b013e318053716a

M3 - Review article

C2 - 17483689

AN - SCOPUS:34247871430

SN - 0022-3069

VL - 66

SP - 329

EP - 336

JO - Journal of neuropathology and experimental neurology

JF - Journal of neuropathology and experimental neurology

IS - 5

ER -

The etiopathogenesis of Parkinson disease and suggestions for future research. Part II

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this